THIS SBIR PHASE I CONTRACT IS FOR A WEARABLE ALCOHOL BIOSENSOR THAT QUANTIFIES BAC IN REAL TIME.

该方法已经过验证，相对于血液测量的标准误差已被量化为低至4.9 mg/dL（0.0049%）。[AD]2技术公司正在与dyonomics公司合作，dyonomics公司已经验证并商业化了饱和肌肉氧（SmO2）技术。除了使用近红外光谱（NIRS）来评估BAC， [AD]2 Technologies正在探索算法开发，以结合许多其他现成的参数，如心率、ecg、加速度计等，以便更好地告知用户的BAC。该设备将通过蓝牙进行通信，电池寿命超过12小时，以4hz的速率进行实时测量，并配有智能手机应用程序用于数据存储和读出。由于先进的技术成熟度和已被证明的商业化道路，这种设备的预期上市时间应该不到两年。

The method has been validated and the standard error relative to blood measurements has been quantified as low as 4.9 mg/dL (0.0049%). [AD]2 Technologies is collaborating with a company, Dynometrics Inc., which has already validated and commercialized this technology with saturated muscle oxygen (SmO2). In addition to using NIR spectroscopy (NIRS) to evalute BAC, [AD]2 Technologies is exploring algorithm development to incorporate many other ready available parameters such as heart rate, ecg, accelerometer, etc. in order to better inform the user's BAC. The device will communicate via Bluetooth, have a battery life over 12 hours, perform real-time measurements at a rate of 4 Hz, and have an accompanying smartphone application for data storage and readout. The anticipated time-to-market for such a device should be less than two years because of the advanced technology maturity and the proved path to commercialization.